血清嗜铬粒蛋白A在嗜铬细胞瘤和副神经节瘤中的应用价值

中华养生保健 ›› 2022, Vol. 40 ›› Issue (20): 9-11.

血清嗜铬粒蛋白A在嗜铬细胞瘤和副神经节瘤中的应用价值

高洪波¹, 邸玉青^2,*, 刘建通³, 李隆敏¹, 李赟¹, 赵春元¹, 邵玉军¹

1.北京核工业医院核素诊疗中心,北京,102413;
2.北京核工业医院心内科,北京,102413;
3.北京核工业医院普通外科,北京,102413

出版日期:2022-10-16 发布日期:2022-10-14
通讯作者: 邸玉青,E-mail：diyq-2002@163.com。
作者简介:高洪波（1982.3-）,男,满族,籍贯：河北省承德市,硕士研究生,副主任医师,研究方向：恶性肿瘤核素治疗。
基金资助:
中国宝原科研基金（ZGBYKY-2021-002）; 北京核工业医院院长基金（YZJJ-2017-002）

Ro1e of Serum CgA Determination for Pheochromocytoma and Paraganglioma

GAO Hong-bo¹, DI Yu-qing^2,*, LIU Jian-tong³, LI Long-min¹, LI Yun¹, ZHAO Chun-yuan¹, SHAO Yu-jun¹

1. Department of Radionuclide Treatment Center, Beijing Nuclear Industry Hospital, Beijing, 102413, China;
2. Department of Cardiology, Beijing Nuclear Industry Hospital, Beijing, 102413, China;
3. Department of General Surgery, Beijing Nuclear Industry Hospital, Beijing, 102413, China

Online:2022-10-16 Published:2022-10-14

摘要/Abstract

摘要： 目的探讨血清嗜铬粒蛋白A（CgA）在嗜铬细胞瘤和副神经节瘤（pheochromocytoma and paraganglioma,PPGL）中的诊断及疗效评价的价值。方法选取2017年6月~2021年6月在北京核工业医院核素诊疗中心住院行¹³¹I-间位碘代苄胍（¹³¹I-metaiodobenzyl guaniodine,¹³¹I-MIBG）治疗的PPGL患者80例,采用双抗体夹心酶联免疫吸附试验（ELISA）检测患者血清CgA水平,评价CgA在转移性PPGL及进展期PPGL中的表达及意义。记录PPGL患者的临床病理特征（性别、年龄、肿瘤功能状态、有无远处转移）,根据疗效评价结果,分为治疗有效组和治疗无效组,对两组CgA水平进行比较。结果 PPGL患者血清CgA水平与患者的性别、年龄、肿瘤功能状态无关,差异无统计学意义（P>0.05）。PCC组与PGL组CgA水平相当,差异无统计学意义（P>0.05）。治疗无效组CgA水平明显高于治疗有效组,差异具有统计学意义（P<0.05）。结论血清CgA在诊断及评价进展期及转移性PPGL方面有一定的意义。

关键词: 嗜铬粒蛋白A, 嗜铬细胞瘤, 副神经节瘤, 酶联免疫吸附试验

Abstract: Objective To explore the disease diagnosis and evaluation value of serum chromaffin A (CgA) in pheochromocytoma and paraganglioma (PPGL). Methods A total of 80 patients with PPGL who were hospitalized and treated with ¹³¹I-metaiodobenzyl guaniodine (¹³¹I-MIBG) from June 2017 to June 2021 were selected in Beijing Nuclear Industry Hospital Radionuclide Diagnostic and Treatment Center. Serum CgA levels were detected by double-antibody sandwich enzyme-linked immunosorptive assay (ELISA), and the expression and significance of CgA in metastatic and advanced PPGL were evaluated. The clinicopathological characteristics (sex, age, tumor functional status, and the presence or absence of distant metastasis) of PPGL patients were recorded, and the levels of CgA were grouped and compared. Results There was no significant difference in serum CgA level in PPGL patients with different gender, age, tumor site and tumor functional status (P>0.05). The level of CgA in PCC group and PGL group was similar, and there was no statistical significance (P>0.05). The level of CgA in the ineffective group was significantly higher than that in the effective group, and the difference was statistically significant (P<0.05). Conclusion Serum CgA determination has certain significance in the diagnosis and evaluation value of disease progression and metastatic PPGL.

Key words: chromogranin A, pheochromocytoma, paraganglioma, Enzyme-linked immunosorbent assay

中图分类号:

R736.6

高洪波, 邸玉青, 刘建通, 李隆敏, 李赟, 赵春元, 邵玉军. 血清嗜铬粒蛋白A在嗜铬细胞瘤和副神经节瘤中的应用价值[J]. 中华养生保健, 2022, 40(20): 9-11.

GAO Hong-bo, DI Yu-qing, LIU Jian-tong, LI Long-min, LI Yun, ZHAO Chun-yuan, SHAO Yu-jun. Ro1e of Serum CgA Determination for Pheochromocytoma and Paraganglioma[J]. ZHONGHUA YANGSHENG BAOJIAN, 2022, 40(20): 9-11.

参考文献

[1] 史轶繁. 协和内分泌和代谢学[M].北京:科学出版社,1999:1222-1223.
[2] 中华医学会内分泌学分会,嗜铬细胞瘤和副神经节瘤诊断治疗专家共识(2020版)[J].中华内分泌代谢杂志,2020,36(9):737-750.
[3] Lloyd R V, Osamura R Y, Kloeppel G, et al.WHO classification of tumours of endocrine Organs[M]. 4th ed. Lyon:International Agency for Research on Cancer(ICRC),2017,183-189.
[4] DeLellis R A, Lloyd R V. World Health Organization classification of tumours pathology and genetics tumours of endocrine organs[M]. 3rd ed. Lyon:International Agency for Research on Cancer(ICRC),2004,147-150.
[5] 曾正陪. 嗜铬细胞瘤的诊断及其发病机制研究[J].中华内分泌代谢杂志,2005,21(5):395-397.
[6] Eisenhuauer E A, Therasse P, Bogaerts J, et al.New response evaluation criteria in solid tumors: revised RECIST guideline(wersion 1.1)[J]. Eur J Cancer,2009,45:228-247.
[7] 张永学,黄钢,匡安仁,等.核医学[M].北京:人民卫生出版社,2010: 8,434.
[8] 陈湘,李勇,陈放.VEGF和NSE在良恶性嗜铬细胞瘤中的表达及意义[J].现代泌尿生殖肿瘤杂志,2010,4(2):90-93.
[9] Noto R B, Pryma D A, Jensen J, et al.Phase 1 study of High-Specific-Activity I-131 MIBG for Metastatic and/or Recurrent Pheochromocytoma or Paraganglioma[J]. J Clin Endocrinol Metab,2018,103(1):213-220.
[10] 金从军,邵玉军,曾正陪,等.¹³¹I-间位碘代苄胍治疗恶性嗜铬细胞瘤/副神经节瘤的临床疗效分析[J].中华泌尿外科杂志,2015,36(1):24-28.
[11] National Comprehensive Cancer Network. NCCN Guidelines Version 1[EB/OL]. (2020-04-12)[2022-05-18]. www.nccn.org/patients.html.
[12] Louthan O.Chromogranin a in physiology and oncology[J]. Folia Biol (Praha) ,2011,57(5):173-181.
[13] Grossrubatscher E, Dalino P, Vignati F, et al.The role of chromogranin A in the management of patients with pheochromocytoma[J]. Clin Endocrinol(Oxf), 2006,65(3):287-293.
[14] Unger N, Hinrichs J, Deutschbein T, et al.Plasma and urinary metanephrines determined by an enzyme immunoassay, but not serum chromogranin A for the diagnosis of pheochromocytoma in patients with adrenal mass[J]. Exp Clin Endocrinol Diabetes, 2012,120(8):494-500.
[15] Giovanella L, Ceriani L.Serun chromogranin-alpha immunoradiometric assay in the diagnosis of pheochromocytoma[J]. Int J Biol Markers,2002,17(2):130-134.
[16] 吴俊,卢仁泉,郭林.血清嗜铬粒蛋白A检测在神经内分泌肿瘤中的应用价值[J].检验医学,2019,34(2):122-125.
[17] Plouon P F, Amar L, Dekkers O M, et al.European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a pheochromocytoma and paraganglioma[J]. Eur J Endocrinol, 2016,174(5):G1-G10.
[18] 胡玉懿,吴蕙,韩序,等.ELISA双抗体夹心法检测嗜铬蛋白A的性能评价及临床应用[J].检验医学,2018,33(1):55-59.
[19] Zuber S, Wesley R, Prodanov T, et al.Clinical utility of chromogranin A in SDHx-related paragangliomas[J]. Eur J Clin Invest, 2014,44(4):365-371.
[20] 冯超,嗜铬粒蛋白A的生物学特性与嗜铬细胞瘤诊断的相关研究[D].北京:北京协和医学院,2008.